Levent Selamoglu is a pioneer in the pharmaceutical industry, with over four decades of experience driving innovation, growth, and transformation across global markets. His strategic leadership has been pivotal in shaping the pharmaceutical landscape in Central & Eastern Europe, the Middle East and Africa.
Levent led Mustafa Nevzat Pharma (MN Pharma) into Turkey’s first and only US FDA-approved pharmaceutical company. Under his leadership, MN Pharma became a leading injectables-focused manufacturer and was responsible for producing Europe’s first biosimilar monoclonal antibody product (Infliximab, biosimilar Remicade). MN Pharma was acquired by Amgen (US-based multinational biologics company) for a record valuation of $700m in 2012. Prior to this, he held leadership positions at GlaxoSmithKline where he drove growth across Turkey and the Middle East.
Levent serves as the Frontier Zdravlje Chairman and also holds board memberships at Frontier Pharma, Avacare Global Healthcare, Humanis Pharmaceuticals, Saya Holding, Imuneks Pharma, and Folkart Yapı and Perfektup Packaging. Levent is also the Chairman of Afrigen Biologics, a WHO and MPP backed vaccines hub based in South Africa and focused on developing and manufacturing mRNA technologies.
Beyond corporate leadership, he actively contributes to industry development as the part of the Turkish Pharmaceutical Manufacturers Association and was an Executive Committee Member for Pharmaceuticals at TUBITAK. He is involved in regulatory advancements, innovation, and policy initiatives that drive progress in healthcare. Levent is a resident of Istanbul and has two children and a grandchild.
Meet Other Board Members
